TELEFLEX INC 8-K

What Happened
Teleflex Inc. (TFX) filed an 8-K on March 17, 2026 updating investors on two previously announced equity purchase agreements entered December 9, 2025. The OEM transaction with Lotus US Bidco Inc. (an affiliate of Montagu Private Equity and Kohlberg & Co.) saw the Hart‑Scott‑Rodino (HSR) waiting period expire effective 11:59 p.m. ET on March 13, 2026, clearing one regulatory condition. The Acute Care and Interventional Urology transaction with Intersurgical Limited received an FTC Second Request on March 11, 2026, which extends the HSR waiting period and delays clearance. The company expects the OEM deal to close in Q3 2026 and the Acute Care and Urology deal in the second half of 2026, subject to remaining regulatory approvals and other closing conditions. The 8‑K was signed by Daniel V. Logue on March 17, 2026.

Key Details

• Agreements originally signed: December 9, 2025 (OEM Agreement and Acute Care & Urology Agreement).
• OEM purchaser: Lotus US Bidco Inc. (affiliate of Montagu Private Equity LLP and Kohlberg & Co., L.L.C.). HSR waiting period expired March 13, 2026. OEM Transaction currently anticipated to close in Q3 2026.
• Acute Care & Urology purchaser: Intersurgical Limited. FTC issued a Second Request on March 11, 2026, extending the HSR waiting period (until 30 days after substantial compliance). Transaction currently anticipated to close in H2 2026.
• The two transactions are separate and may close independently; closings remain subject to other regulatory approvals and conditions. No purchase price or financial terms were disclosed in this filing.

Why It Matters
These updates affect the timing and regulatory risk around Teleflex’s planned divestitures. The OEM deal advancing past the HSR waiting period reduces one regulatory hurdle and may shorten the path to closing, while the FTC Second Request for the Acute Care and Urology sale creates a delay and extends uncertainty for that transaction. Because the filing does not disclose financial terms or expected proceeds, investors should watch for future company disclosures for the impact on Teleflex’s financials and strategy. Keywords: divestiture, acquisition, HSR, FTC Second Request, regulatory approval.